67 search results for: coexisting diseases
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.
2025 ADVENT Forum | Potential for Disease Modification in the Airway
Unlock new perspectives on managing chronic airway diseases. Profs. Leonard Bacharier, Eugenio De Corso, Stella Lee, Marc Miravitlles, Celeste Porsbjerg, Klaus Rabe, and Martin Wagenmann – share their collective wisdom and experience on the evolving landscape of therapeutic strategies aimed at truly modifying disease progression, offering renewed hope for patients and practitioners alike.
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.
EAACI PAAM 2025 | How Type 2 Inflammation Shapes a Lifetime
Join ADVENT faculty members Len Bacharier, Antonella Cianferoni, and Andre Moreira for an educational symposium highlighting type 2 inflammation and its shared and distinct roles in multiple chronic pediatric diseases.
Can advanced systemic therapies modify pathomechanisms in AD?
Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.
Can early intervention modify the course of AD?
Dr. Amy Paller emphasizes that early intervention in children can alter disease progression. Depending on the severity, this can be achieved with topical interventions or systemic therapies.
What proportion of patients can achieve control in CRSwNP?
Join Prof. Hellings and Prof. Corso in dicussion on the factors affecting complete control of CRSwNP, including treatment types, comorbidities, and the need for more data on biologics.
It Takes a Village: Patient-Centered Care in Pediatric EoE
Learn from Prof. Papadopoulou as she highlights the importance of collaboration of multiple specialties in the care of pediatric EoE.
EoE: A Chronic, Progressive, Type 2 Inflammatory Disease Infographic
Learn about key drivers of type 2 inflammation in EoE and how they mediate progressive esophageal remodeling and impact patient burden
EADV 2025 Congress
ADVENT at EADV 2025: Join Sanofi and Regeneron for three educational symposia on AD, CSU, and BP.
Master Clinician Video | Empowering Our Patients: Patient-Centered Practice and Follow-Up in the Clinic (Chapter 4)
This chapter focuses on the importance of shared decision-making and regular, long-term monitoring of histology and endoscopy, not just symptoms.
EoE Burden and Pathophysiology of Type 2 Inflammation
Learn about the significant burden that patients with EoE experience, and the role of type 2 inflammation in this chronic, progressive disease.
